PROBLEM OF INFLUENZA PROPHYLAXIS BY VACCINES


Cite item

Full Text

Abstract

Scientific data is presented and problems of influenza prophylaxis in various age groups are discussed. Influenza prophylaxis in neonates is possible by inducing maternal antibodies, this dictates the necessity of influenza vaccination in pregnancy. Problems of influenza prophylaxis are most pressing in the group of children from 6 months to 2 years of age. More effective vaccines that do not cause adverse reactions are necessary for the children of this age group. Influenza prophylaxis in healthy working adults is most important for reducing economical impact during influenza epidemics. Influenza prophylaxis in the elderly is reasonable by using novel and more effective vaccines with adjuvants. The optimal method for influenza prophylaxis in the population in general is mass vaccination of children (80%), when, besides the induction of protection in children, influenza morbidity may decrease up to 80% in the other age groups of unvaccinated population.

About the authors

Yu. Z Gendon

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

Yu. M Vasiliev

Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia

References

  1. Гендон Ю.З. Живые холодоадаптированные реассортантные гриппозные вакцины. Вопр. вирусол. 2001, 3: 5-12.
  2. Гендон Ю.З. Массовая вакцинопрофилактика гриппа у детей как главный фактор борьбы с эпидемиями гриппа. Журн. микробиол. 2007, 4: 78-85.
  3. Гендон Ю.З. Проблемы профилактики гриппа у беременных женщин и новорожденных детей. Вопр. вирусол. 2009, 4: 4-10.
  4. Гендон Ю.З. Проблемы профилактики гриппа у маленьких детей. Там же. 2006, 2: 4-10.
  5. Ahmed A., Nicholson K., Nguyen-van Tam J. et al. Effectiveness of influenza vaccine in reducing hospital admissions during the 1989 - 1990 epidemic. Epidemiol. Infect. 1997, 118: 27-33.
  6. Arguedas A., Soley C., Lindert K. Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. N. Engl. J. Med. 2010, 362: 370-372.
  7. CDC. Preliminary assessment of the effectiveness of the 2003 - 2004 inactivated influenza vaccines - Colorado, December 2003. Morb. Mortal. Wkly Rep. 2004, 53: 8-11.
  8. CDC. Prevention and control of influenza: recommendation of the Advisory Committee on immunization practices. Morb. Mortal. Wkly Rep. Recomm. Rep. 2004, 53 (RR-6): 1-40.
  9. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on immunization practices. Ibid. 2010, 59 (RR-8): 1-62.
  10. Das Gupta R., Guest J. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK. Pharmacoeconomics. 2002, 20: 475-484.
  11. de Bruijn I., Meyer I., Gerez L. et al. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine. 2007, 26: 119-127.
  12. Dodds L., McNeil S., Fell D. et al. Impact of influenza exposure on rates of hospital admissions and physician visits because of respiratory illness among pregnant women. Canad. Med. Ass. J. 2007, 176: 463-468.
  13. Elveback L., Fox J., Ackerman E. et al. An influenza simulation model for immunization studies. Am. J. Epidemiol. 1976, 103: 152-165.
  14. Fiore A., Shay D., Broder K. et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. Morb. Mortal. Wkly Rep. Recomm. Rep. 2009, 58 (RR-8): 1-52.
  15. Fleming D., Watson J., Nicholas S. et al. Study of the effectiveness of influenza vaccination in the elderly in the epidemic of 1989 - 1990 using a general practice database. Epidemiol. Infect. 1995, 115: 581-589.
  16. Fox J., Cooney M., Hall C. et al. Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness. Am. J. Epidemiol. 1982, 116: 228-242.
  17. Frank A., Taber L., Wells C. et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J. Infect. Dis. 1981, 144: 433-441.
  18. Freeman M., Jacobziner H., Parkter J. et al. Maternal mortality in the epidemic of Asian influenza, New York City, 1957. Am. J. Obstet. Gynecol. 1958, 76: 897-902.
  19. Gabutti G., Guido M., Quattrocchi M. et al. Surveillance of influenza in Apulia, Italy, 1999 - 2000, 2000 - 2001, 2001 - 2002, and 2002 - 2003 seasons. Med. Mal. Infect. 2004, 34: 469-476.
  20. Gasparini R., Pozzi T., Montomoli E. et al. Increased immunogenicity of the MF59adjuvanted influenza vaccine compared to a conventional subunit vaccine in elderly subjects. Eur. J. Epidemiol. 2001, 17: 135-140.
  21. Ghendon Y., Kaira A., Elshina G. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol. Infect. 2006, 134: 71-78.
  22. Glezen W., Payne A., Snyder D. et al. Mortality and influenza. J. Infect Dis. 1982, 146: 313-321.
  23. Gorse G., O’Connor T., Young S. et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine. 2003, 21: 2133-2144.
  24. Harris J. Influenza occurring in pregnant women. J. Am. Med. Ass. 1919, 14: 978-980.
  25. Hartert T., Neuzil K., Shintani A. et al. Maternal morbidity and perinatal outcomes among pregnant women with respiratory hospitalizations during influenza season. Am. J. Obstet. Gynecol. 2003, 189: 1705-1712.
  26. Heikkinen T., Silvennoinen H., Peltola V. et al. Burden of influenza in children in the community. J. Infect. Dis. 2004, 190: 1369-1373.
  27. Heinonen O., Slone D., Shapiro S. Immunization agent. Birth defects and drugs in pregnancy. D. Kaufman (ed.). Publishing Sciences Group., 1997, p. 314-321.
  28. Hurwitz E., Haber M., Chang A. et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. J. Am. Med. Ass. 2000, 284: 1677-1682.
  29. Jamieson D., Honein M., Rasmussen S. et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009, 374: 451-458.
  30. Kanra G., Marchisio P., Feiterna-Sperling C. et al. Comparison of immunogenicity and tolerability of a virosome-adjuvanted and a split influenza vaccine in children. Pediatr. Infect. Dis. J. 2004, 23: 300-306.
  31. Kwong J., Stukel T., Lim J. et al. The effect of universal influenza immunization on mortality and health care use. PLoS Med. 2008, 5: e211.
  32. Monto A., Davenport F., Napier J. et al. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. J. Infect. Dis. 1970, 122: 16-25.
  33. Monto A., Ohmit S., Petrie J. et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N. Engl. J. Med. 2009, 361: 1260-1267.
  34. Neuzil K., Mellen B., Wright P. et al. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N. Engl. J. Med. 2000, 342: 225-231.
  35. Neuzil K., Reed G., Mitchel E. et al. Impact of influenza on acute cardiopulmonary hospitaliza- tions in pregnant women. Am. J. Epidemiol. 1998, 148: 1094-1102.
  36. Nguyen-van-Tam J. Epidemiology of influenza. In: Textbook of Influenza. K. Nicholson, R. Webster, A. Hay (ed.). Blackwell Sci., 1998, p. 181-206.
  37. Nichol K., Lind A., Margolis K. et al. The effectiveness of vaccination against influenza in healthy, working adults. N. Engl. J. Med. 1995, 333: 889-893.
  38. Nichol K., Mendelman P., Mallon K. et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. J. Am. Med. Ass. 1999, 282: 137-144.
  39. Nicholson K. Human influenza. In: Textbook of Influenza. K. Nicholson, R. Webster, A. Hay (ed.). Blackwell Sci., 1998, p. 219-264.
  40. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine. 2001, 19: 2673- 2680.
  41. Puig-Barbera J., Diez-Domingo J., Varea A. et al. Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly. Vaccine. 2007, 25: 7313-7321.
  42. Reichert T., Sugaya N., Fedson D. et al. The Japanese experience with vaccinating schoolchil- dren against influenza. N. Engl. J. Med. 2001, 344: 889-896.
  43. Ryan J., Zoellner Y., Gradl B. et al. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine. 2006, 24: 6812-6822.
  44. Salk J., Menke W., Francis T. A clinical, epide- Контактная информация: Гендон Ю.З., miological and immunological evaluation of vaccination against epidemic influenza. Am. J. Hyg. 1945, 42: 57-93.
  45. Salleras L., Dominguez A., Pumarola T. et al. Effectiveness of virosomal subunit influenza vaccine in preventing influenza-related illnesses and its social and economic consequences in children aged 3-14 years: a prospective cohort study. Vaccine. 2006, 24: 6638-6642.
  46. Steinhoff M., Omer S., Roy E. et al. Influenza immunization in pregnancy - antibody responses in mothers and infants. N. Engl. J. Med. 2010, 362: 1644-1646.
  47. Takahashi H., Tanaka Y., Ohyama T. et al. Evaluation of a mass influenza vaccination cam- paign. Jpn. J. Infect. Dis. 2001, 54: 184-188.
  48. Treanor J., Dumyati G., O’Brien D. et al. Evaluation of cold-adapted, reassortant influenza B virus vaccines in elderly and chronically ill adults. J. Infect. Dis. 1994, 169: 402-407.
  49. Waddington C., Walker W., Oeser C. et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. Brit. Med. J. 2010, 340: c2649.
  50. Warburton M., Jacobs D., Langsford W. et al. Herd immunity following subunit influenza vaccine administration. Med. J. Aust. 1972, 2: 67-70.
  51. Weycker D., Edelsberg J., Halloran M. et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine. 2005, 23: 1284-1293.
  52. WHO. Influenza vaccines. WHO position paper. Wkly Epidemiol. Rec. 2005, 80: 279-287.
  53. Zaman K., Roy E., Arifeen S. et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl. J. Med. 2008, 359: 1555-1564.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Gendon Y.Z., Vasiliev Y.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС77-75442 от 01.04.2019 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies